The risk profiles were based on data from the National Health and Nutrition Examination Survey 2011-2020. Chronic kidney ...

FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...

Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

People with chronic kidney disease, Type 2 diabetes or both were predicted to have elevated cardiovascular disease (CVD) risk 8 to 28 years sooner than someone without those conditions, according to a ...

Risk factors most closely tied to MetS include age as the likelihood increases with age, and a personal or family history of ...

As part of its ongoing RAK diabetes Challenge community initiative, RAK Hospital held an insightful Diabeat Webinar on the LINK between diabetes and kidney disease, shedding light on the prevention ...

ProKidney's REACT® therapy shows kidney function stabilization. Find out why PROK stock is risky due to cash issues and ...

Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral ...

As part of its ongoing RAK Diabetes Challenge community initiative, RAK Hospital held an insightful Diabeat Webinar on the ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

The annual meeting of the American Society of Nephrology (Kidney Week) was held this year from Oct. 23 to 27 in San Diego, ...